FDA panels recommend expanding REMS, requiring prescriber education, for ER/LA opioids

Two Food and Drug Administration advisory committees have unanimously agreed that the current risk evaluation and mitigation strategy (REMS) for extended-release and long-acting opioid analgesic...
Source: Rheumatology News - Category: Rheumatology Source Type: research